免疫检查点抑制剂相关的肺动脉高压：一项药物警戒研究。
Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.
机构信息
Department of Medical Pharmacology and Toxicology, Montpellier, University Hospital, Montpellier, France.
Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-Immune Diseases, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.
出版信息
Cancer Immunol Immunother. 2022 Dec;71(12):3093-3097. doi: 10.1007/s00262-022-03208-2. Epub 2022 May 26.
Abstract
Immune checkpoint inhibitors (ICI) restore immune response against cancer cells that can lead to immune-related adverse effects. While cardiovascular immune-related adverse effects are known to be associated with checkpoint inhibitors, recent case reports have raised concerns about the potential association with pulmonary hypertension (PH). By using the global pharmacovigilance database VigiBase, we investigated the onset of PH associated with ICI and propose a comprehensive description of the 42 cases of PH reported with ICI recorded in this database. Through this study and review of the cases published in the literature, we discuss the possible link between PH and ICI in the context of cancer in order to better understand this rare but potentially fatal event.
摘要
免疫检查点抑制剂 (ICI) 恢复了针对癌细胞的免疫反应，从而导致免疫相关不良反应。虽然心血管免疫相关不良反应与检查点抑制剂有关，但最近的病例报告引起了人们对其与肺动脉高压 (PH) 之间潜在关联的关注。通过使用全球药物警戒数据库 VigiBase，我们调查了与 ICI 相关的 PH 发病情况，并提出了该数据库中记录的 42 例与 ICI 相关的 PH 报告病例的综合描述。通过这项研究以及对文献中发表的病例的回顾，我们讨论了 PH 与癌症环境中的 ICI 之间的可能联系，以便更好地理解这种罕见但可能致命的事件。
相似文献
1
Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.免疫检查点抑制剂相关的肺动脉高压：一项药物警戒研究。
Cancer Immunol Immunother. 2022 Dec;71(12):3093-3097. doi: 10.1007/s00262-022-03208-2. Epub 2022 May 26.
2
Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.免疫检查点抑制剂时代药物性葡萄膜炎谱的演变来自世卫组织的药物警戒数据库。
J Autoimmun. 2020 Jul;111:102454. doi: 10.1016/j.jaut.2020.102454. Epub 2020 Apr 14.
3
Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.神经免疫不良反应与免疫检查点抑制剂相关：使用 FAERS 数据库的回顾性药物警戒研究。
J Neurooncol. 2021 Mar;152(1):135-144. doi: 10.1007/s11060-020-03687-2. Epub 2021 Jan 9.
4
Immune checkpoint inhibitor-associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study.免疫检查点抑制剂相关毛细血管渗漏综合征：系统评价和全球药物警戒研究。
J Intern Med. 2023 Jul;294(1):58-68. doi: 10.1111/joim.13641. Epub 2023 Apr 20.
5
Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study.免疫检查点抑制剂治疗的肾毒性：一项药物警戒研究。
Nephrol Dial Transplant. 2022 Jun 23;37(7):1310-1316. doi: 10.1093/ndt/gfab187.
6
Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.免疫检查点抑制剂相关的心血管毒性：FDA 不良事件报告系统的更新综合不成比例分析。
J Clin Pharm Ther. 2022 Oct;47(10):1576-1584. doi: 10.1111/jcpt.13707. Epub 2022 Jun 20.
7
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.免疫检查点抑制剂相关的心血管毒性：一项观察性、回顾性、药物警戒研究。
Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12.
8
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
9
Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.免疫检查点抑制剂使用后的结肠炎：向 FDA 不良事件报告系统提交的自发报告的真实世界分析。
Int Immunopharmacol. 2020 Jul;84:106601. doi: 10.1016/j.intimp.2020.106601. Epub 2020 May 16.
10
Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.药物警戒学的启示：免疫检查点抑制剂治疗后的肺部免疫相关不良事件。
Lung. 2021 Apr;199(2):199-211. doi: 10.1007/s00408-021-00425-x. Epub 2021 Feb 22.
引用本文的文献
1
Microbiota Transplant Therapy Is Safe and Feasible in Pulmonary Arterial Hypertension.微生物群移植疗法在肺动脉高压中是安全可行的。
JACC Basic Transl Sci. 2025 Aug 12;10(9):101347. doi: 10.1016/j.jacbts.2025.101347.
2
Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.肺癌与心血管疾病：共同的病理生理学与治疗——新发毒性
JACC CardioOncol. 2025 Jun;7(4):325-344. doi: 10.1016/j.jaccao.2025.05.003.
3
Therapeutic targets for pulmonary arterial hypertension: insights into the emerging landscape.肺动脉高压的治疗靶点：对新出现格局的见解
Expert Opin Ther Targets. 2025 Jun;29(6):327-343. doi: 10.1080/14728222.2025.2507034. Epub 2025 May 21.
4
Pulmonary Arterial Hypertension in a Patient With Metastatic Lung Cancer on Pembrolizumab: Whom to Blame?帕博利珠单抗治疗转移性肺癌患者时发生的肺动脉高压：该归咎于谁？
J Med Cases. 2025 Apr;16(4):153-157. doi: 10.14740/jmc5115. Epub 2025 Apr 26.
5
Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications.癌症治疗相关的肺动脉高压和右心室功能障碍：病因及预后意义
Rev Cardiovasc Med. 2024 Mar 5;25(3):87. doi: 10.31083/j.rcm2503087. eCollection 2024 Mar.
6
Inflammatory Alterations to Renal Lymphatic Endothelial Cell Gene Expression in Mouse Models of Hypertension.高血压小鼠模型中肾脏淋巴内皮细胞基因表达的炎症改变。
Kidney Blood Press Res. 2024;49(1):588-604. doi: 10.1159/000539721. Epub 2024 Jul 22.
7
The impact of pulmonary artery to ascending aorta diameter ratio progression on the prognosis of NSCLC patients treated with immune checkpoint inhibitors.肺动脉与升主动脉直径比值进展对免疫检查点抑制剂治疗 NSCLC 患者预后的影响。
Front Immunol. 2024 Jan 29;15:1302233. doi: 10.3389/fimmu.2024.1302233. eCollection 2024.
8
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study.标准与延长免疫检查点抑制剂给药间隔的临床安全性比较：一项真实世界回顾性队列研究。
ESMO Open. 2023 Dec;8(6):102070. doi: 10.1016/j.esmoop.2023.102070. Epub 2023 Nov 21.
本文引用的文献
1
Role of the Immune System Elements in Pulmonary Arterial Hypertension.免疫系统元件在肺动脉高压中的作用
J Clin Med. 2021 Aug 23;10(16):3757. doi: 10.3390/jcm10163757.
2
Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation.免疫检查点抑制剂疗法对右心室功能和肺动脉扩张的不良影响。
Pulm Circ. 2021 Feb 9;11(1):2045894021992236. doi: 10.1177/2045894021992236. eCollection 2021 Jan-Mar.
3
Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy.解除制动：一例免疫检查点抑制剂治疗诱发肺动脉高压的病例报告
Pulm Circ. 2020 Nov 11;10(4):2045894020960967. doi: 10.1177/2045894020960967. eCollection 2020 Oct-Dec.
4
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.尼伏鲁单抗可增加非小细胞肺癌治疗患者的肺动脉压。
Cancer Chemother Pharmacol. 2020 Oct;86(4):497-505. doi: 10.1007/s00280-020-04142-9. Epub 2020 Sep 16.
5
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.免疫检查点抑制剂相关性心肌炎：病理生理特征、诊断与治疗
J Am Heart Assoc. 2020 Jan 21;9(2):e013757. doi: 10.1161/JAHA.119.013757.
6
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.晚期癌症患者中免疫检查点抑制剂相关肺炎的相对风险和发病率：一项荟萃分析
Front Pharmacol. 2018 Dec 11;9:1430. doi: 10.3389/fphar.2018.01430. eCollection 2018.
7
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.血流动力学定义和肺动脉高压的最新临床分类。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
8
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.免疫检查点抑制剂相关的心血管毒性：一项观察性、回顾性、药物警戒研究。
Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12.
9
Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.调节性 T 细胞在保护女性免受肺动脉高压中的主导作用。
Circ Res. 2018 Jun 8;122(12):1689-1702. doi: 10.1161/CIRCRESAHA.117.312058. Epub 2018 Mar 15.
10
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.免疫检查点抑制剂相关心脏毒性的临床特征、管理及结局
Circulation. 2017 Nov 21;136(21):2085-2087. doi: 10.1161/CIRCULATIONAHA.117.030571.
Zotero 插件